TY  - JOUR
T1  - A new psychotropic agent
AU  - Snyder SH, Faillace LA, Weingartner H
Y1  - 1969/07/01
N1  - 10.1001/archpsyc.1969.01740190097014
JO  - Archives of General Psychiatry
SP  - 95
EP  - 01
VL  - 21
IS  - 1
N2  - PSYCHEDELIC drugs include a number of compounds of widely varying chemical structures which produce, however, similar subjective effects. The spectrum of the psychedelic syndrome embraces mood changes, alterations in body image, central sympathetic stimulation, changes in thought processes, perceptual distortions, and hallucinations, and is essentially the same for drugs of lysergic acid, tryptamine, and mescaline classes. The possibility that these similar effects result from interaction of these drugs on a common receptor site is supported by the existence of cross-tolerance among psychedelic drugs of different structures1,2 and by similarities of their molecular conformation3 and electronic configuration.4,5An important therapeutic use of psychedelic drugs has been as facilitators of psychotherapy. In this "psycholytic" usage the facet of drug action applied is its capacity to enhance self-awareness and permit new insight. The failure of this type of therapy
SN  - 0003-990X
M3  - doi: 10.1001/archpsyc.1969.01740190097014
UR  - http://dx.doi.org/10.1001/archpsyc.1969.01740190097014
ER  -